在癌症治疗中SGLT2抑制剂的研究进展
Xiaoyong Miao1, Jianing Zhang2, Weiyan Huang2
1Department of Anesthesiology, Naval Medical Center, Naval Medical University, Shanghai, People's Republic of China.
Drug design, development and therapy
|January 28, 2025
概括
糖共运输体2 (SGLT2) 抑制剂通过增加尿路葡萄糖分泌来降低血糖. 新兴研究表明,SGLT2抑制剂也可能抑制瘤生长,提供潜在的新型癌症疗法.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖共运输体2 (SGLT2) 抑制剂是一种新的降糖药物.
- SGLT2蛋白主要位于脏的近端管道中,调节葡萄糖的再吸收.
- 最近的发现表明,SGLT2在各种癌症类型中表达.
研究的目的:
- 审查SGLT2在癌症发展和进展中的作用.
- 探索SGLT2抑制可能影响瘤的机制.
- 讨论SGLT2抑制剂作为抗癌剂的潜力.
主要方法:
- 对SGLT2功能,癌症表达和治疗潜力研究的文献综述.
- 对SGLT2在瘤发生过程中的机制进行现有研究的分析.
- 关于SGLT2抑制剂在癌症中的临床和临床前研究数据的综合.
主要成果:
- SGLT2在瘤发生和瘤进展中发挥作用.
- 抑制SGLT2可能会抑制瘤生长.
- 作为一种新的抗癌治疗策略,SGLT2抑制剂显示出前景.
结论:
- SGLT2 抑制剂代表了癌症治疗的有希望的途径.
- 需要进一步的研究,以充分阐明SGLT2抑制的抗癌作用.
- 准SGLT2可以提供一种新的方法来管理各种癌症.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.7K
07:29Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
19.5K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Glucose Transporters
22.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
